HOUSE_OVERSIGHT_028419.jpg
3.3 MB
Extraction Summary
2
People
4
Organizations
0
Locations
7
Events
3
Relationships
3
Quotes
Document Information
Type:
Congressional report/oversight document
File Size:
3.3 MB
Summary
This document, from a House Oversight file, details the business practices of the pharmaceutical company Celgene concerning its drugs Thalomid and Revlimid between 2000 and 2017. It outlines allegations of improper 'off-label' marketing, significant price increases, and aggressive strategies to extend its patent monopoly and block competition from generic drug makers. The document includes quotes from a Celgene executive, a federal regulatory agency, and a generic drug industry representative.
People (2)
| Name | Role | Context |
|---|---|---|
| Mr. Hugin | Top executive at Celgene |
Repeatedly referred to Thalomid and Revlimid as key to Celgene's financial future. Quoted from a 2004 investor confer...
|
| Michael Brzica | Vice president for federal government affairs at the Association for Accessible Medicines |
Quoted as saying Celgene has gone to great lengths to protect its drug monopoly by building 'walls' around it.
|
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Celgene |
Pharmaceutical company that markets Thalomid and Revlimid. Accused of improper marketing, settling a lawsuit in 2017,...
|
|
| the agency |
A federal regulatory agency (implied to be the FDA) that issued a formal warning letter to Celgene in 2000 for improp...
|
|
| Association for Accessible Medicines |
The lobbying group for the generic drug industry.
|
|
| HOUSE_OVERSIGHT |
Appears in the footer of the document, suggesting it is part of a file from the House Oversight Committee.
|
Timeline (7 events)
2000
A federal agency issued a formal warning letter to Celgene for improperly marketing Thalomid.
Celgene
the agency
Relationships (3)
The agency issued a warning letter to Celgene in 2000 for improper marketing.
Celgene's actions to extend its drug monopoly are criticized by the association, which represents the generic drug industry.
Key Quotes (3)
"Perhaps more than for any other available drug, the need to provide and distribute thalidomide responsibly is essential to the public health."Source
— the agency
(From a formal warning letter sent to Celgene in 2000 regarding the marketing of Thalomid.)
HOUSE_OVERSIGHT_028419.jpg
Quote #1
"Thalomid is important, because it is the financial engine that drives us."Source
— Mr. Hugin
(Statement made at an investor conference in 2004, highlighting the financial importance of the drug to Celgene before it had full approval for cancer treatments.)
HOUSE_OVERSIGHT_028419.jpg
Quote #2
"They’ve gone to pretty great lengths to protect that drug and to build as many walls around it as they can."Source
— Michael Brzica
(Describing Celgene's aggressive campaign to extend its monopoly on Revlimid and Thalomid and prevent generic competition.)
HOUSE_OVERSIGHT_028419.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document